945459-79-0

Upstream product

• 676-97-1 methylphosphonic acid dichloroanhydride 
• 3536-96-7 vinylmagnesium chloride 
• 100-46-9 benzylamine 
• 945460-42-4 methyl divinyl phosphine oxide 

Downstream Products

• 945460-43-5 4-methyl-[1,4]azaphosphinane-4-oxide 
• 1260402-00-3 N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-((E)-3-(4-methyl-1,4-azaphosphino-1-yl)prop-1-enyl)quinazolin-4-amine 
• 1260401-98-6 N-(3-chloro-4-((6-methylpyridin-2-yl)methoxy)phenyl)-6-(5-((4-methyl-1,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260401-97-5 N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-6-(5-((4-methyl-1,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260401-94-2 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(3-(4-methyl-1,4-azaphosphino-1-yl)propyl)quinazolin-4-amine 
• 1260401-93-1 N-(3-chloro-4(3-fluorobenzyloxy)phenyl)-6-(3-(4-methyl-1,4-azaphosphine1-yl)propan-1-yn)quinazolin-4-amine 
• 1260401-90-8 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((4-methyl-1,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260402-11-6 N-(3-chloro-4-(pyrazin-2-ylmethoxy)phenyl)-6-(5-((4-methy1-l,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260402-04-7 2-((2-chloro-4-(6-(5-((4-methyl-1,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-ylamino)phenoxy)methyl)pyridine 1-oxide 
• 1260402-03-6 N-(4-(3-fluorobenzyloxy)-3-bromophenyl)-6-(5-((4-methyl-1,4-azaphosphino-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 1260402-01-4 N-(4-(6-methylpyridin-3-yloxy)-3-methylphenyl)-6-(5-((4-methyl-1,4-azaphosphinan-1-yl)methyl)furan-2-yl)quinazolin-4-amine 

Relevant academic research and scientific papers

PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

INHIBITORS OF TYROSINE KINASES AND USES THEREOF

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-rnediated diseases or conditions or tyrosine, kinase-dependent diseases or conditions are provided.